
The FDA granted priority review to sonesitatug vedotin in second- and later-line CLDN18.2-positive gastric, GEJ, or esophageal adenocarcinoma, with a decision expected in the second quarter of 2027.
In this slide show we present sage words for the young oncologist starting today from colleagues who are well-established in their fields. What advice would you give?






